Navigation Links
Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 8:30 AM Pacific Time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.   Replays of the presentation will be available at the same location for 30 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
3. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
4. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
5. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
6. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
7. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
9. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
10. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 7D Surgical announced today that ... U.S. Food and Drug Administration (FDA) and a ... North American commercial launch of its innovative Machine-vision ... the 7D Surgical System.  The ... and machine vision algorithms to eliminate the long-standing ...
(Date:1/23/2017)... DUBLIN , Jan 23, 2017 Research and ... Market Analysis & Trends - Product - Forecast to 2025" report ... Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
(Date:1/23/2017)... January 23, 2017 Varias ... enal) y el riesgo de ... a pabetalone    Resverlogix Corp. ("Resverlogix" ... preliminares de un ensayo en fase 1 con sede ... riñón (renal) severa. Los datos demostraron unos resultados importantes ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG ... Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at ... was founded in 2008 to address the limitations of fatigue monitoring technologies within ...
(Date:1/23/2017)... ... ... plastic balance boards have been around since at least the 1950s and are a great ... and only balance board to use a patent-pending design featuring high-pressure inflation technology and drop-stitch ... well as skill-level adjustable for all ages and abilities. The board can be rolled ...
(Date:1/23/2017)... Grants Pass, OR (PRWEB) , ... January 23, 2017 , ... ... disease, took to the air to educate listeners about the benefits of making new ... in the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become ...
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, ... serve as a healthcare industry expert at the 2017 Sector Summit hosted by ... Inside Indiana Business host Gerry Dick, will feature an employer and an association ...
(Date:1/23/2017)... ... 2017 , ... Moisture measurement is a necessary process step ... to success. Selecting an inappropriate measurement method can cause costly errors, and poor ... equipment. Rare or expensive substances are wasted and production may even be stopped ...
Breaking Medicine News(10 mins):